PUBLISHER: The Business Research Company | PRODUCT CODE: 1957606
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957606
Personalized genomics refers to the application of an individual's genetic data to customize medical care, lifestyle guidance, and disease risk evaluations based on their unique DNA makeup. It is used in areas such as predicting disease susceptibility, optimizing drug response, and supporting preventive healthcare approaches.
The main test types in personalized genomics include oncology testing, infectious disease testing, neurological testing, cardiovascular testing, and other categories. Oncology testing comprises diagnostic procedures used to detect, diagnose, and monitor cancer through genetic, molecular, and imaging techniques. The technologies utilized in oncology testing include polymerase chain reaction (PCR)-based tests, microarray-based assays, sequencing-based tests, and other advanced methods. These tests are applied across areas such as diagnostics, precision medicine, wellness, reproductive health, sports nutrition, lifestyle management, and others, and they serve end users including hospitals, clinics, research institutions, pharmaceutical and biotechnology companies, diagnostic laboratories, and other organizations.
Tariffs have influenced the personalized genomics market by increasing costs for imported sequencing instruments, reagents, and testing consumables, impacting overall test pricing. Sequencing-based tests and advanced molecular technologies are most affected, particularly in regions dependent on imports such as Asia-Pacific and parts of Europe. These cost pressures can slow adoption in diagnostics and wellness applications. However, tariffs are also encouraging domestic manufacturing, local innovation, and regional capacity building for genomics technologies.
The personalized genomics market research report is one of a series of new reports from The Business Research Company that provides personalized genomics market statistics, including personalized genomics industry global market size, regional shares, competitors with a personalized genomics market share, detailed personalized genomics market segments, market trends and opportunities, and any further data you may need to thrive in the personalized genomics industry. This personalized genomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The personalized genomics market size has grown rapidly in recent years. It will grow from $9.45 billion in 2025 to $10.96 billion in 2026 at a compound annual growth rate (CAGR) of 16.0%. The growth in the historic period can be attributed to declining costs of genetic sequencing, increasing prevalence of chronic and genetic diseases, growth in research-based genomics studies, expansion of diagnostic laboratory infrastructure, early adoption of precision medicine approaches.
The personalized genomics market size is expected to see rapid growth in the next few years. It will grow to $19.61 billion in 2030 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to integration of genomics into routine clinical practice, rising demand for personalized medicine, advancements in sequencing technologies, expansion of wellness and ancestry testing, growing investments by pharmaceutical and biotechnology companies. Major trends in the forecast period include rising adoption of direct-to-consumer genetic testing, growing use of pharmacogenomics in treatment planning, increasing demand for preventive and predictive healthcare, expansion of genetic testing in reproductive health, rising consumer awareness of lifestyle and wellness genomics.
The increasing prevalence of chronic diseases is anticipated to drive the growth of the personalized genomics market in the coming years. Chronic diseases are long-term health conditions that require continuous management and include diabetes, cardiovascular diseases, hypertension, and other complex disorders. The rise in chronic diseases is mainly attributed to aging populations, sedentary lifestyles, unhealthy dietary patterns, and environmental influences that contribute to the simultaneous development of multiple conditions. Personalized genomics aids chronic disease management by enabling large-scale genotyping and sequencing to categorize individuals based on genetic risk, supporting more accurate diagnoses, targeted treatments, and improved preventive strategies. For instance, in April 2025, according to the U.S. Centers for Disease Control and Prevention (CDC), a US-based organization, 76.4% of U.S. adults-approximately 194 million people-had at least one of 12 selected chronic conditions, while 51.4% (around 130 million individuals) were living with two or more of these conditions. Therefore, the rising prevalence of chronic diseases is fueling the growth of the personalized genomics market.
Major companies operating in the personalized genomics market are concentrating on the development of innovative solutions, such as personalized genomics platforms, to deliver customized insights related to health, wellness, and disease prevention. A personalized genomics platform is a system designed to analyze an individual's genetic information and provide tailored recommendations and insights concerning health status, wellness optimization, and disease risk. For example, in September 2024, Neuberg Diagnostics Private Limited, an India-based diagnostic services company, launched Geniee Decode Your DNA, a customized genomics platform. This personalized genomics platform delivers individualized health, nutrition, and medication insights based on a person's genetic profile, helping to optimize wellness, prevent disease, and personalize treatments for improved health outcomes.
In August 2024, Labcorp, a US-based diagnostics and laboratory services company, acquired selected assets of Invitae Corporation for an undisclosed amount. Through this acquisition, Labcorp seeks to enhance its specialty testing portfolio and strengthen the use of genetic data to advance clinical trials and personalized care in oncology and rare disease areas. Invitae Corporation is a US-based medical genetics company specializing in comprehensive genetic testing and genomic data services.
Major companies operating in the personalized genomics market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation
North America was the largest region in the personalized genomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized genomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the personalized genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The personalized genomics market consists of revenues earned by entities by providing services such as pharmacogenomic services, genetic counseling, and customized fitness plans. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized genomics market also includes sales of genetic testing kits, health risk assessments, and nutrigenomics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Personalized Genomics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses personalized genomics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for personalized genomics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The personalized genomics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.